“Good clarification”

On the 12th September 2019 Dr Sameer Jauhar shared on social media the above correction, as published in the Daily Mail, describing it as a “good clarification” The Council for … Continue reading “Good clarification”

Trainees’ Workshop

As part of the 2019 Summer Meeting the British Association for Psychopharmacology has organised a ‘Trainees’ Workshop’ chaired by Professor Jeremy Hall and with the following five speakers: I have … Continue reading Trainees’ Workshop

The Narrative Controllers

Science is important to us all. This post is an attempt to explore some of the broad issues that we need to consider to ensure scientific integrity. Science is more … Continue reading The Narrative Controllers

Crappy Branded Stuff

It has been many years now since ABPI introduced a new Code that put an end to the ‘gifting’ of relatively low value merchandise to healthcare professionals from industry representatives. … Continue reading Crappy Branded Stuff

‘Realistic Medicine: Valuing People”

Alongside my NHS Lothian colleagues in psychiatry I have received an invitation to the Realistic Medicine Conference for 2018. It is entitled “Valuing People”. I have repeatedly made clear my … Continue reading ‘Realistic Medicine: Valuing People”

Professor Stephen Lawrie

This is my latest post as part of a series reporting the available information on competing financial interests in ‘key opinion leaders’ in British psychiatry. Professor Stephen Lawrie’s “Disclosure UK” … Continue reading Professor Stephen Lawrie

Data Privacy For Healthcare Professionals (provided by SUNOVION)

In my previous post I outlined the material sent to me as an NHS doctor by the pharmaceutical company SUNOVION. This material was to market a new product. I was … Continue reading Data Privacy For Healthcare Professionals (provided by SUNOVION)

Latuda promotion “high standards had not been maintained”

The following is a PMCPA (Prescription Medicines Code of Practice Authority) Case Ruling on Latuda promotion from July 2016. Sunovion were found to have breached Clauses 8.2 and 9.1 Page … Continue reading Latuda promotion “high standards had not been maintained”

Marketing of Latuda in NHS Scotland

In an NHS e-mail with a wide distribution list, I was invited to this marketing event. Though it is titled “Current updates in treatment for schizophrenia” the following programme demonstrates … Continue reading Marketing of Latuda in NHS Scotland

“A robust learning environment for healthcare professionals”

I have recently posted on the promotion of Lurasidone (Latuda) in the UK. This has raised concerns for me about transparency of conflicts of interest for some of the key … Continue reading “A robust learning environment for healthcare professionals”

Lurasidone – financial conflicts of interest

The launch in the UK of Lurisidone began in August 2014. My previous post on Lurasidone (Latuda) which has now been marketed in the UK followed the financial interests of … Continue reading Lurasidone – financial conflicts of interest

Lurasidone – “Special Article”

I noticed this “Special Article” published in the October edition of the British Journal of Psychiatry. It details a novel antipsychotic medication called Lurasidone  (trade name Latuda): I would anticipate … Continue reading Lurasidone – “Special Article”